Caris Life Sciences (CAI) Gains from Investment Securities (2024 - 2026)
Caris Life Sciences (CAI) recorded quarterly Gains from Investment Securities of $40000.0 in Q1 2026, up 100.21% quarter-over-quarter from -$19.4 million in Q4 2025, and up 211.11% on a YoY basis from $12857.1 in Q1 2025.
Caris Life Sciences (CAI) Gains from Investment Securities (2024 - 2026) Analysis & Trends
Caris Life Sciences' Gains from Investment Securities history runs 3 years deep, the most recent figure standing at $40000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 211.11% year-over-year to $40000.0; the TTM figure through Mar 2026 stood at -$1.1 million (changed N/A YoY), while the FY2025 annual figure was -$1.2 million, down 267.72% from the prior year.
- Gains from Investment Securities was $40000.0 for Q1 2026 at Caris Life Sciences, up from -$19.4 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $18.6 million in Q3 2025 to a low of -$19.4 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged -$64428.6 across 3 years, with a median of $40000.0 in 2026.
- Biggest YoY gain for Gains from Investment Securities was 13541.18% in 2025; the steepest drop was 3399.49% in 2025.
- A 3-year view of Gains from Investment Securities shows it stood at $589000.0 in 2024, then sank by 3399.49% to -$19.4 million in 2025, then surged by 100.21% to $40000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $40000.0 (Q1 2026), -$19.4 million (Q4 2025), and $18.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Caris Life Sciences | 5.22 Bn | 4.40 Bn | 171.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,000.00 |
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | -19.43 Mn |
| Dec 31, 2025 | -19.43 Mn |
| Sep 30, 2025 | 18.55 Mn |
| Sep 30, 2025 | 18.55 Mn |
| Jun 30, 2025 | -298,000.00 |
| Jun 30, 2025 | -298,000.00 |
| Mar 31, 2025 | -36,000.00 |
| Mar 31, 2025 | -36,000.00 |
| Dec 31, 2024 | 589,000.00 |
| Dec 31, 2024 | 589,000.00 |
| Sep 30, 2024 | 136,000.00 |
| Sep 30, 2024 | 136,000.00 |